Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.44 |
| ▸ | CTSL | P07711 | 6/20 | 0.44 |
| ▸ | CTSS | P25774 | 6/20 | 0.44 |
| ▸ | CTSB | P07858 | 4/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | CTSV | O60911 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771052 | 1.00 | CTSK (0.44) | CTSKCTSLCTSSCTSBPDE2A | |
| SCHEMBL7565521 | 0.85 | SIGMAR1 (0.43) | CTSKCTSLCTSS | |
| SCHEMBL7565531 | 0.85 | SIGMAR1 (0.43) | CTSKCTSLCTSS | |
| SCHEMBL4841725 | 0.84 | CTSK (0.52) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4841704 | 0.84 | CTSK (0.43) | CTSKCTSLCTSSCTSBPDE2A | |
| SCHEMBL7428878 | 0.74 | CTSK (0.53) | CTSKCTSLCTSSCTSBPDE2A | |
| SCHEMBL5096700 | 0.74 | CTSK (0.41) | CTSKCTSLCTSSCTSBPDE2A | |
| SCHEMBL4924362 | 0.73 | CTSK (0.56) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL7633224 | 0.73 | CTSK (0.56) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6592566 | 0.73 | CTSK (0.36) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885CTSL 25/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.